EUVIMEDEUVIMED entdecken
Crossref

ZDHHC5-mediated BRAF palmitoylation activates the MAPK pathway and drives cholangiocarcinoma progression

Chunxi Li, Xiezong Hu, Ziqiou Zhang, Hongrui Zhu, Qi Wu, Hui Zhang, Li Wang, Yao Liu, Jiabei Wang, Lianxin Liu, Qingsong Hu

Cancer Letters · 2026-08 · 653 · 218569

DOI: 10.1016/j.canlet.2026.218569 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026-08. Verfasst von Chunxi Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, The First Affiliated Hospital of USTC, State Key Laboratory of Immune Responses and Immunotherapy, Centre for Le…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Proto-Oncogene Proteins B-raf, Bile Duct Neoplasms, Acyltransferases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Natural Science Foundation of Anhui Province, National Science and Technology Major Project, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cholangiocarcinoma is a highly malignant tumor with an increasing incidence around the world. Discovery of novel molecular targets and effective therapies for cholangiocarcinoma are urgently needed. Palmitoylation is a reversible lipid modification mainly catalyzed by ZDHHC family palmitoyltransferases. However, its function and underlying mechanisms in cholangiocarcinoma remain poorly understood. Here, we found that protein palmitoylation levels and ZDHHC5 expression were upregulated in cholangiocarcinoma. Knockdown of ZDHHC5 inhibited the growth of cholangiocarcinoma. Mechanistically, ZDHHC5 modulates the activity of MAPK signaling pathway by regulating palmitoylation of BRAF at Cys194/195. Palmitoylation facilitates the membrane localization of BRAF and stabilizes BRAF protein. Either knockdown of ZDHHC5 or disruption of palmitoylation sites of BRAF inhibited ERK signaling. Furthermore, we found that cholangiocarcinoma cells expressing high levels of ZDHHC5 exhibited increased activities of MAPK signaling pathway and increased sensitivities to MAPK signaling pathway inhibitors. This study identifies a previously unknown ZDHHC5-BRAF-ERK axis that promotes the growth of cholangiocarcinoma and represents a potential crucial role in therapeutic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaProto-Oncogene Proteins B-rafBile Duct NeoplasmsAcyltransferasesMAP Kinase Signaling SystemHumansLipoylationCell Line, TumorAnimalsCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticRNA InterferenceMice, NudeProtein Kinase Inhibitors

Substanzen

Proto-Oncogene Proteins B-rafAcyltransferasesBRAF protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, The First Affiliated Hospital of USTC, State Key Laboratory of Immune Responses and Immunotherapy, Centre for Leading Medicine and Advanced Technologies of IHM, Division of Life Scie…

Förderung

  • Natural Science Foundation of Anhui Province
  • National Science and Technology Major Project
  • National Natural Science Foundation of China
  • Chinese Academy of Sciences

Zitieren

APA

Li, C., Hu, X., Zhang, Z., Zhu, H., Wu, Q., Zhang, H., Wang, L., Liu, Y., Wang, J., Liu, L., & Hu, Q. (2026). ZDHHC5-mediated BRAF palmitoylation activates the MAPK pathway and drives cholangiocarcinoma progression. Cancer Letters, 653, 218569. https://doi.org/10.1016/j.canlet.2026.218569

Vancouver

Li C, Hu X, Zhang Z, Zhu H, Wu Q, Zhang H, et al. ZDHHC5-mediated BRAF palmitoylation activates the MAPK pathway and drives cholangiocarcinoma progression. Cancer Letters. 2026;653:218569. doi:10.1016/j.canlet.2026.218569

BibTeX
@article{Li2026,
  author = {Li, Chunxi and Hu, Xiezong and Zhang, Ziqiou and Zhu, Hongrui and Wu, Qi and Zhang, Hui and Wang, Li and Liu, Yao and Wang, Jiabei and Liu, Lianxin and Hu, Qingsong},
  title = {ZDHHC5-mediated BRAF palmitoylation activates the MAPK pathway and drives cholangiocarcinoma progression},
  journal = {Cancer Letters},
  year = {2026},
  volume = {653},
  pages = {218569},
  doi = {10.1016/j.canlet.2026.218569}
}
Kostenlos starten →